BTG plc
10 Fleet Place
Limeburner Lane
London
EC4M 7SB
United Kingdom
Tel: 44-0-20-7575-0000
Fax: 44-0-20-7575-0010
Website: http://www.btgplc.com/
Email: info@btgplc.com
142 articles about BTG plc
-
Boston Scientific Closes Acquisition of BTG plc.
8/19/2019
Boston Scientific Corporation announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement.
-
NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®
7/11/2019
BTG plc, the global healthcare company, highlighted the first publication of National Comprehensive Cancer Network pediatric acute lymphoblastic leukemia guidelines including consideration of Voraxaze®.
-
Trial Finds Patients Receiving CroFab® Antivenom Less Likely to Use Opioids for Pain Control
4/29/2019
BTG plc announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine.
-
Arizona Patients Successfully Receive the World’s First Bioconvertible IVC Filter Commercially Offered In US
12/3/2018
BTG plc today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter.
-
Boston Scientific Announces Recommended Offer to Acquire BTG plc.
11/20/2018
Transaction would expand peripheral interventions portfolio with minimally-invasive treatments for cancers and vascular conditions
-
Less than a week after Boston Scientific announced that it was undergoing a restructuring that could result in some job losses, the company announced that it will acquire U.K.-based BTG plc., a surgical device manufacturer for about $4.2 billion.
-
BTG Sentry Bioconvertible IVC Filter 2-year Study Results Show Zero Tilt, Migration, Perforation, Fracture, or Embolization
11/7/2018
BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances (VIVA) conference in Las Vegas.
-
Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman
10/11/2018
Exclusive worldwide licence deal adding to Carrick's rapid pipeline expansion
-
FDA Approves CroFab® Product Improvements
9/13/2018
Updated label describes extended shelf life and removal of mercury
-
PERT Consortium and BTG Form Strategic Partnership
6/21/2018
Strategic partnership with the PERT ConsortiumTM to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERTTM programs across the U.S.
-
OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions
4/27/2018
BTG plc highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California.
-
BTG Release: Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS Therapy Protocols for Pulmonary Embolism
12/14/2017
At full enrollment, KNOCOUT PE is expected to include up to 100 centers internationally.
-
BTG plc: Northwestern University Adopts Y90 TARE With TheraSphere as First-Line Treatment for HCC
12/12/2017
BTG today announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere, Northwestern University, Illinois has adopted Y90 TARE with TheraSphere as the primary trans-arterial LRT for patients with hepatocellular carcinomalimited to the liver.
-
BTG plc Release: Vistogard And Voraxaze Added To Revised Guidelines For Stocking Of Antidotes In U.S. Hospitals
9/13/2017
-
BTG plc And SIO Expand Immuno-Oncology / Interventional Oncology Grant Programme
8/21/2017
-
BTG plc Release: ACCESS PTS Study Demonstrates Efficacy Of EKOS Therapy For Post-Thrombotic Syndrome
6/16/2017
-
BTG plc Release: New Study Shows Patients Treated With CroFab Have Improved Recovery From Copperhead Envenomation
6/13/2017
-
BTG plc Release: New Study Shows IO Loop Improves Patient Follow-Up, Engagement And Satisfaction Following Treatment With TheraSphere
6/12/2017
-
BTG plc Release: OPTALYSE PE Study Demonstrates Safety And Efficacy Of Shorter, Lower Dose EKOS Therapy For Pulmonary Embolism
5/22/2017
-
BTG plc Release: First European Patients Treated With Dc Bead Lumi Radiopaque Drug-Eluting Beads
4/20/2017